NurExone Partners with NanoPass to Advance Exosome Delivery for Eye and Skin Therapies
Event summary
- NurExone and NanoPass have signed an MOU to evaluate NanoPass’s MicronJet™ platform for delivering NurExone’s exosome formulations in eye and skin applications.
- The collaboration will focus on preclinical studies for suprachoroidal delivery in ophthalmology and intradermal delivery in dermatology and aesthetics.
- NurExone will own preclinical proof-of-concept results, with newly developed IP jointly owned.
- The global regenerative aesthetics market is projected to grow from $17.7 billion in 2026 to $28.9 billion by 2030.
The big picture
This collaboration aligns with the broader trend of biotech companies seeking precision delivery solutions for regenerative therapies. The partnership could enhance NurExone’s ability to scale and commercialize its exosome-based treatments, particularly in the rapidly growing aesthetics market. The success of this technical integration will be critical for NurExone’s strategic positioning in both therapeutic and commercial applications.
What we're watching
- Technical Feasibility
- Whether NanoPass’s MicronJet™ platform can demonstrate practical, minimally invasive, and consistent administration of NurExone’s exosome formulations in preclinical studies.
- Market Potential
- The pace at which the regenerative aesthetics market will expand and how NurExone’s collaboration with NanoPass positions it to capture this growth.
- Intellectual Property
- How the joint ownership of newly developed IP will impact future commercialization and strategic partnerships.